Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD (TELO - DMRD)

Sir Mortimer B. Davis - Jewish General Hospital

Status: Not yet enrolling

Conditions: Multiple Myeloma

Treatments: Diagnostic Test: Standard of care

Study type: Observational

Funder types: Other

Identifiers

NCT05530096

Telo Genomics Study

Details and patient eligibility

About

The purpose :

Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.

Enrollment: 70 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed MM diagnosis
• Transplant eligible patients in a first remission
• Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed)
• Availability of deidentified patient's demographic and clinical follow up data
• Receiving standard of care treatment
• Able to provide informed consent

Exclusion criteria

• Failure to meet inclusion criteria

Trial design

70 participants in 1 patient group

MRD level group

Description:

Participants will be defined as diagnosed with multiple myeloma

Treatment:

Diagnostic Test: Standard of care